{
  "docId": "019de073-9947-75c9-ab6d-01a31b39af7e",
  "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f",
  "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 12,
  "pageCount": 24,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 50,
  "notes": "The slide includes a disclaimer that cross-study comparisons are unreliable due to differences in study design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/12",
  "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e",
  "deckJsonHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e.json",
  "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1.Alvarado, D. et al. Allergy (2022) doi:10.1111/all.15262. Each of the candidates were tested in a different clinical trial and comparing results from different studies may be unreliable due to differences between the studies with respect to study design, objectives, and other parameters, and there can be no assurances regarding the performance of THB001 relative to Barzovolimab or any other drug in a head-to-head trial. Mean(SD).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de03a2c9-1fc9-4291-9fce-3b87846d52b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.76,
        "x": 0.12,
        "y": 0.25
      },
      "kind": "table",
      "text": "THB001 and Barzovolimab hematology data tables",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a08116c-e053-4940-9539-df2af490878b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Hematology Parameter Comparison –THB001 and Barzovolimab in NHVs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db59e3c7-39aa-4993-be65-fede3e75ca6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.3,
        "y": 0.15
      },
      "kind": "title",
      "text": "Change from Baseline to Post-Baseline Minimum",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a54de048-2ae6-49e5-a975-c5f25c217b0d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "c1b7c037-94bb-4fe8-97ef-c63f5ff00669",
      "evidence": "The THB001 and Barzovolimab hematology data tables present comparative data in a clear and organized manner.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 21,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1637e937-fd9b-4682-939c-d684884ac925",
      "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.",
      "position": 0,
      "objective": "What is the cost of not treating mast cell-mediated diseases effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}